View source for Janssen Vaccines

{{short description|Biotechnology subsidiary of Johnson & Johnson}}
{{coord|52.1655|4.4673|display=title}}
{{Infobox company
| name = Janssen Vaccines
| logo = Janssen Pharmaceuticals logo.svg
| logo_size = 220px
| image = File:Archimedesweg 4 Leiden.jpg
| former_name = Crucell
| type = [[Subsidiary]]
| foundation = {{start date and age|2000}}
| hq_location = Archimedesweg 4
| hq_location_city = [[Leiden]]
| hq_location_country = Netherlands
| key_people = {{ubl|Ronald Brus ([[Chief executive officer|CEO]])|Jan Pieter Oosterveld ([[chairman]] of the [[supervisory board]])}}
| industry = [[Biotechnology]]
| products = [[Vaccine]]s and [[antibody|antibodies]]
| owner =
| parent = [[Johnson & Johnson]]
| homepage =
}}
'''Janssen Vaccines''', formerly '''Crucell''', is a [[biotechnology]] company specializing in [[vaccines]] and biopharmaceutical technologies.
It was formed when [[Johnson & Johnson]] acquired the Dutch biotech company Crucell. Janssen Vaccines is part of Johnson & Johnson Innovative Medicine business segment.
__TOC__
==History==
In 1993 [[Introgene]], Crucell's predecessor, was established as a [[University spin-off|spin-off]] of [[Leiden University]]. The company formed a partnership with [[Genzyme]] to collaborate on its vector technology and viral-based products. In 1999 the company founded [[Galapagos Genomics]] as a joint venture together with [[Tibotec]]. In 2000 IntroGene acquired [[U-Bisys]] to form Crucell.{{citation needed|date=October 2022}}
In 2006, Crucell and Swiss Berna Biotech; Swedish SBL Vaccines and US-based Berna Products joined forces to become the sixth largest vaccine company worldwide, with their own clinical programs.{{citation needed|date=October 2022}}
On 7 January 2009 Crucell released a [[press release]] saying Crucell and [[Wyeth]] were in discussion on a merger of the two companies. On 26 January 2009 Crucell released another press release saying the discussions on a combination of Crucell and Wyeth was discontinued due to [[Pfizer]]'s acquisition of Wyeth.{{citation needed|date=October 2022}}
In September 2009 [[Johnson & Johnson]] bought 18% stake in Crucell for €302 million in order to collaborate on the development of a [[Influenza vaccine|flu vaccine]].<ref>{{cite news |url=https://www.reuters.com/article/rbssPharmaceuticals%20-%20Generic%20&%20Specialty/idUSLS21205620090928 |title=Johnson & Johnson buys 18 pct stake in Crucell |work=[[Reuters]] |last=Gray-Block |first=Aaron |date=28 September 2009 |access-date=28 September 2009}}</ref> This followed Crucell's discovery of [[CR6261]], a potent human antibody that neutralizes a broad range of influenza A viruses. J&J acquired the rest of the company in October 2010, taking its stake to over 95% by February 2011<ref>{{cite news|last=Solsman|first=Joan E.|title=J&J: Sufficient Number Of Crucell Holders Tender Shares|url=https://www.wsj.com/article/BT-CO-20110217-717650.html|access-date=27 February 2011|newspaper=[[The Wall Street Journal]]|date=17 February 2011|agency=[[Dow Jones Newswires]]}}</ref><ref>{{cite web |title=J&J aiming to buy vaccine maker Crucell for $2.3 billion |url=https://www.reuters.com/article/us-crucell/jj-aiming-to-buy-vaccine-maker-crucell-for-2-3-billion-idUSTRE68G0RX20100917 |website=Reuters |language=en |date=17 September 2010}}</ref> and delisting the company from stock exchanges two months later.<ref>{{cite news|last=Gray-Block|first=Aaron|title=Crucell to be delisted after J&J buyout|url=https://www.reuters.com/article/crucell-idUSLDE73A0FR20110411|access-date=16 April 2011|date=11 April 2011|work=[[Reuters]]}}</ref>
After the takeover by Johnson & Johnson in 2011, Crucell was assigned to [[Janssen Pharmaceuticals]] division. In 2014, the subsidiary was renamed from Crucell to Janssen Vaccines.<ref>{{cite web |url= https://www.devex.com/organizations/crucell-44661 |publisher= DevEx |title= Crucell |date= 2015 }}</ref><ref>{{cite web |url= https://www.bloomberg.com/profile/company/0836856D:SW |title= Janssen Vaccines AG |publisher= Bloomberg |work= Company Profiles |date= 2020 }}</ref>
=== COVID-19 vaccine development ===
{{main article|Janssen COVID-19 vaccine}}
Janssen Vaccines in Leiden developed the [[COVID-19 vaccines]] for Johnson & Johnson. Initial production of the vaccine is happening at [[Janssen Biotech]] in Leiden, Netherlands. The vaccine stands out because it is the first single-shot vaccine against [[COVID-19]] that was developed during the [[COVID-19 pandemic]].{{citation needed|date=October 2022}}
==References==
<references />
{{Johnson & Johnson}}
[[Category:University spin-offs]]
[[Category:Johnson & Johnson subsidiaries]]
[[Category:Companies based in South Holland]]
[[Category:Biotechnology companies of the Netherlands]]
[[Category:Biotechnology companies established in 2000]]
[[Category:2000 establishments in the Netherlands]]
[[Category:2009 mergers and acquisitions]]
[[Category:Vaccine producers]]
[[Category:COVID-19 vaccine producers]]